Current Ratio
since 2005
Calculation
Bristol-Myers Squibb Co., current ratio, long-term trends, calculation
| Current ratio | = | Current assets1 | ÷ | Current liabilities1 | |
|---|---|---|---|---|---|
| Dec 31, 2024 | 1.25 | = | 29,780) | ÷ | 23,774) |
| Dec 31, 2023 | 1.43 | = | 31,770) | ÷ | 22,262) |
| Dec 31, 2022 | 1.25 | = | 27,273) | ÷ | 21,890) |
| Dec 31, 2021 | 1.52 | = | 33,262) | ÷ | 21,868) |
| Dec 31, 2020 | 1.58 | = | 30,192) | ÷ | 19,080) |
| Dec 31, 2019 | 1.60 | = | 29,354) | ÷ | 18,304) |
| Dec 31, 2018 | 1.61 | = | 17,160) | ÷ | 10,654) |
| Dec 31, 2017 | 1.55 | = | 14,854) | ÷ | 9,563) |
| Dec 31, 2016 | 1.55 | = | 13,704) | ÷ | 8,841) |
| Dec 31, 2015 | 1.30 | = | 10,415) | ÷ | 8,017) |
| Dec 31, 2014 | 1.73 | = | 14,608) | ÷ | 8,461) |
| Dec 31, 2013 | 1.52 | = | 18,916) | ÷ | 12,440) |
| Dec 31, 2012 | 1.15 | = | 9,521) | ÷ | 8,279) |
| Dec 31, 2011 | 1.97 | = | 15,318) | ÷ | 7,780) |
| Dec 31, 2010 | 1.97 | = | 13,273) | ÷ | 6,739) |
| Dec 31, 2009 | 2.21 | = | 13,958) | ÷ | 6,313) |
| Dec 31, 2008 | 2.20 | = | 14,763) | ÷ | 6,710) |
| Dec 31, 2007 | 1.20 | = | 10,348) | ÷ | 8,644) |
| Dec 31, 2006 | 1.59 | = | 10,302) | ÷ | 6,496) |
| Dec 31, 2005 | 1.78 | = | 12,283) | ÷ | 6,890) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
The analysis of the financial data over the given periods reveals distinct trends in current assets, current liabilities, and the current ratio, which collectively indicate the liquidity position of the entity.
- Current Assets
- The value of current assets demonstrated significant fluctuations throughout the years. Initially, there was a decline from 12,283 million USD in 2005 to 10,302 million USD in 2006, followed by relatively stable figures around the 10,300 million mark through 2007. A pronounced increase occurred in 2008, reaching 14,763 million USD, followed by minor decreases and increases, with notable volatility observed in 2012 where assets dropped sharply to 9,521 million USD. From 2013 onwards, the trend was generally upward, peaking notably at 29,354 million USD in 2019, and reaching around 29,780 million USD by 2024, albeit with a slight decrease seen in 2022. This pattern suggests periods of both consolidation and expansion in short-term asset holdings.
- Current Liabilities
- Current liabilities also fluctuated over the period. Beginning at 6,890 million USD in 2005, they initially declined and then rose steadily with some variability, peaking at 22,774 million USD by 2024. There was a marked increase from 2013 onward, with a significant jump to 18,304 million USD in 2019 and continued growth thereafter. The liabilities growth trend outpaced that of assets in the later years, indicating a potential increase in short-term obligations.
- Current Ratio
- The current ratio, which is a liquidity metric calculated as current assets divided by current liabilities, reflected variability consistent with the changes in assets and liabilities. It started relatively strong at 1.78 in 2005, dropped to a low of 1.15 in 2012, and then exhibited fluctuations mainly within the range of 1.25 to 1.61 in the subsequent years. Notably, despite the growth in current assets, the current ratio declined to 1.25 by 2024 due to the proportionally greater increase in current liabilities. This suggests a moderate compression of liquidity buffers over time, signaling a tighter liquidity position despite asset growth.
Comparison to Competitors
Bristol-Myers Squibb Co., current ratio, long-term trends, comparison to competitors
| Bristol-Myers Squibb Co. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 1.25 | 0.66 | 1.26 | 1.40 | 1.15 | 1.60 | 1.11 | 1.36 | 1.17 | 4.73 | 1.66 | 2.69 |
| Dec 31, 2023 | 1.43 | 0.87 | 1.65 | 1.68 | 0.94 | 1.43 | 1.16 | 1.25 | 0.91 | 5.69 | 1.75 | 3.99 |
| Dec 31, 2022 | 1.25 | 0.96 | 1.41 | 1.89 | 1.05 | 1.29 | 0.99 | 1.47 | 1.22 | 5.06 | 1.48 | 4.83 |
| Dec 31, 2021 | 1.52 | 0.79 | 1.59 | 1.43 | 1.23 | 1.27 | 1.35 | 1.27 | 1.40 | 3.56 | 1.50 | 4.46 |
| Dec 31, 2020 | 1.58 | 0.84 | 1.81 | 1.86 | 1.40 | 1.40 | 1.21 | 1.02 | 1.35 | 3.63 | 2.13 | 4.33 |
| Dec 31, 2019 | 1.60 | 3.18 | 1.44 | 5.19 | 1.16 | 3.10 | 1.26 | 1.24 | 0.88 | 3.67 | 1.92 | 3.61 |
| Dec 31, 2018 | 1.61 | 0.98 | 2.79 | 1.47 | 1.73 | 3.38 | 1.47 | 1.17 | 1.57 | 4.47 | 1.73 | 3.43 |
| Dec 31, 2017 | 1.55 | 1.28 | 5.49 | 1.43 | 1.32 | 2.74 | 1.41 | 1.33 | 1.35 | 3.82 | 1.34 | 3.28 |
| Dec 31, 2016 | 1.55 | 1.65 | 4.11 | 0.97 | 1.37 | 2.22 | 2.47 | 1.78 | 1.25 | 2.56 | 1.44 | 2.31 |
| Dec 31, 2015 | 1.30 | 1.50 | 4.44 | 1.27 | 1.53 | 2.50 | 2.17 | 1.55 | 1.49 | 3.59 | 1.38 | 2.78 |
| Dec 31, 2014 | 1.73 | 1.41 | 4.95 | 1.75 | 1.09 | 3.07 | 2.36 | 1.77 | 2.67 | 3.31 | 1.22 | 4.20 |
| Dec 31, 2013 | 1.52 | 2.59 | 3.44 | 2.01 | 1.47 | 1.15 | 2.20 | 2.00 | 2.41 | 6.01 | 3.16 | 3.99 |
| Dec 31, 2012 | 1.15 | 2.27 | 3.81 | 1.80 | 1.55 | 1.44 | 1.90 | 1.90 | 2.15 | 7.37 | 2.31 | 3.67 |
| Dec 31, 2011 | 1.97 | — | 4.80 | 1.50 | 1.60 | 5.53 | 2.38 | 2.04 | 2.06 | 4.40 | 1.55 | 3.39 |
| Dec 31, 2010 | 1.97 | — | 3.52 | 1.73 | 2.09 | 2.32 | 2.05 | 1.86 | 2.11 | 3.28 | 2.42 | 2.23 |
| Dec 31, 2009 | 2.21 | — | 4.89 | 1.89 | 1.90 | 2.57 | 1.82 | 1.80 | 1.66 | 4.55 | 2.76 | 4.59 |
| Dec 31, 2008 | 2.20 | — | 3.12 | 1.53 | 0.95 | 3.52 | 1.65 | 1.35 | 1.59 | 6.23 | 2.82 | 4.01 |
| Dec 31, 2007 | 1.20 | — | 2.11 | 1.40 | 2.33 | 4.11 | 1.51 | 1.23 | 2.15 | 2.81 | 1.93 | 2.49 |
| Dec 31, 2006 | 1.59 | — | 1.67 | 1.38 | 1.91 | 3.18 | 1.20 | 1.20 | 2.20 | 10.44 | 1.70 | 3.07 |
| Dec 31, 2005 | 1.78 | — | 2.57 | 1.30 | 1.89 | 6.79 | 2.48 | 1.58 | 1.47 | 8.46 | 1.71 | 3.84 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Bristol-Myers Squibb Co., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Bristol-Myers Squibb Co. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2024 | 1.25 | 1.24 |
| Dec 31, 2023 | 1.43 | 1.27 |
| Dec 31, 2022 | 1.25 | 1.30 |
| Dec 31, 2021 | 1.52 | 1.36 |
| Dec 31, 2020 | 1.58 | 1.37 |
| Dec 31, 2019 | 1.60 | 1.66 |
| Dec 31, 2018 | 1.61 | 1.71 |
| Dec 31, 2017 | 1.55 | 1.74 |
| Dec 31, 2016 | 1.55 | 1.91 |
| Dec 31, 2015 | 1.30 | 1.90 |
| Dec 31, 2014 | 1.73 | 2.19 |
| Dec 31, 2013 | 1.52 | 2.17 |
| Dec 31, 2012 | 1.15 | 2.04 |
| Dec 31, 2011 | 1.97 | 2.30 |
| Dec 31, 2010 | 1.97 | 2.14 |
| Dec 31, 2009 | 2.21 | 1.95 |
| Dec 31, 2008 | 2.20 | 1.66 |
| Dec 31, 2007 | 1.20 | 1.74 |
| Dec 31, 2006 | 1.59 | 1.65 |
| Dec 31, 2005 | 1.78 | 1.82 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Bristol-Myers Squibb Co., current ratio, long-term trends, comparison to industry (health care)
| Bristol-Myers Squibb Co. | Health Care | |
|---|---|---|
| Dec 31, 2024 | 1.25 | 1.14 |
| Dec 31, 2023 | 1.43 | 1.17 |
| Dec 31, 2022 | 1.25 | 1.19 |
| Dec 31, 2021 | 1.52 | 1.24 |
| Dec 31, 2020 | 1.58 | 1.24 |
| Dec 31, 2019 | 1.60 | 1.40 |
| Dec 31, 2018 | 1.61 | 1.45 |
| Dec 31, 2017 | 1.55 | 1.49 |
| Dec 31, 2016 | 1.55 | 1.67 |
| Dec 31, 2015 | 1.30 | 1.66 |
| Dec 31, 2014 | 1.73 | 1.87 |
| Dec 31, 2013 | 1.52 | 1.93 |
| Dec 31, 2012 | 1.15 | 1.81 |
| Dec 31, 2011 | 1.97 | 1.92 |
| Dec 31, 2010 | 1.97 | 1.80 |
| Dec 31, 2009 | 2.21 | 1.75 |
| Dec 31, 2008 | 2.20 | 1.42 |
| Dec 31, 2007 | 1.20 | 1.51 |
| Dec 31, 2006 | 1.59 | 1.39 |
| Dec 31, 2005 | 1.78 | 1.64 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).